Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-08-24

AUTHORS

Jung Hwan Yu, Jung Il Lee, Kwan Sik Lee, Ja Kyung Kim

ABSTRACT

BackgroundDirect-acting antivirals (DAAs) for chronic hepatitis C (CHC) treatment are tolerable and highly effective in a shorter period of time than before. However, resistance-associated variants (RAVs) can affect the efficacy of DAAs. The aim of this study was to investigate the real-life prevalence of RAVs against non-structural protein 5A (NS5A) inhibitors in Korean patients with genotype 1b chronic hepatitis C.MethodsAll consecutive patients with CHC genotype 1b who underwent a RAV test at a single referral hospital were enrolled.ResultsA total of 142 patients (male 53, female 89) were tested for RAVs. The average age of the patients was 58 years. Liver cirrhosis was found in 34.5% (49/142) of patients, and 19.0% (29/142) of patients had previously undergone interferon-based treatment. Twenty-nine patients (20.4%) had RAVs (Y93 or L31). Y93H, L31, or Y93H with L31 were detected in 22 (15.5%), 8 (5.6%), and 1 (0.7%) patients, respectively. The presence of RAV was not affected by previous interferon-based treatment or by the existence of liver cirrhosis. Among 113 patients without baseline NS5A RAVs, 72 patients started daclatasvir (DCV) + asunaprevir (ASV) treatment and 95% (68/72) patients achieved virologic response at week 4. Virologic response at end of treatment and sustained virologic response at 12 weeks after treatment were achieved by 94% (68/72) and 94% (68/72), respectively.ConclusionsIn Korean patients with genotype 1b CHC, 20.4% (29 of 142) of patients showed RAVs against NS5A inhibitors. Patient without RAVs who received treatment with DCV + ASV showed high virologic response rates in Korea. More... »

PAGES

164

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12985-017-0826-1

DOI

http://dx.doi.org/10.1186/s12985-017-0826-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1091326412

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28836992


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Base Sequence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carbamates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Viral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genotype", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepacivirus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatitis C, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferons", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Isoquinolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Cirrhosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prevalence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrrolidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "RNA, Viral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Republic of Korea", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sustained Virologic Response", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Failure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Valine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Viral Nonstructural Proteins", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Gangnam Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, 20, 63-gil, Eonju-ro Gangnam-gu, 06229, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Gangnam Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, 20, 63-gil, Eonju-ro Gangnam-gu, 06229, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yu", 
        "givenName": "Jung Hwan", 
        "id": "sg:person.01010326240.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010326240.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gangnam Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, 20, 63-gil, Eonju-ro Gangnam-gu, 06229, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Gangnam Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, 20, 63-gil, Eonju-ro Gangnam-gu, 06229, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Jung Il", 
        "id": "sg:person.01136317651.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136317651.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gangnam Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, 20, 63-gil, Eonju-ro Gangnam-gu, 06229, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Gangnam Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, 20, 63-gil, Eonju-ro Gangnam-gu, 06229, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Kwan Sik", 
        "id": "sg:person.01017047320.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017047320.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gangnam Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, 20, 63-gil, Eonju-ro Gangnam-gu, 06229, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Gangnam Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, 20, 63-gil, Eonju-ro Gangnam-gu, 06229, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Ja Kyung", 
        "id": "sg:person.0634505520.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634505520.15"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00535-017-1353-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085710678", 
          "https://doi.org/10.1007/s00535-017-1353-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1743-422x-10-355", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026883385", 
          "https://doi.org/10.1186/1743-422x-10-355"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12985-015-0318-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005521011", 
          "https://doi.org/10.1186/s12985-015-0318-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-015-0221-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011803667", 
          "https://doi.org/10.1007/s12325-015-0221-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-016-0354-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017346594", 
          "https://doi.org/10.1007/s12325-016-0354-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-08-24", 
    "datePublishedReg": "2017-08-24", 
    "description": "BackgroundDirect-acting antivirals (DAAs) for chronic hepatitis C (CHC) treatment are tolerable and highly effective in a shorter period of time than before. However, resistance-associated variants (RAVs) can affect the efficacy of DAAs. The aim of this study was to investigate the real-life prevalence of RAVs against non-structural protein 5A (NS5A) inhibitors in Korean patients with genotype 1b chronic hepatitis C.MethodsAll consecutive patients with CHC genotype 1b who underwent a RAV test at a single referral hospital were enrolled.ResultsA total of 142 patients (male 53, female 89) were tested for RAVs. The average age of the patients was 58\u00a0years. Liver cirrhosis was found in 34.5% (49/142) of patients, and 19.0% (29/142) of patients had previously undergone interferon-based treatment. Twenty-nine patients (20.4%) had RAVs (Y93 or L31). Y93H, L31, or Y93H with L31 were detected in 22 (15.5%), 8 (5.6%), and 1 (0.7%) patients, respectively. The presence of RAV was not affected by previous interferon-based treatment or by the existence of liver cirrhosis. Among 113 patients without baseline NS5A RAVs, 72 patients started daclatasvir (DCV)\u00a0+\u00a0asunaprevir (ASV) treatment and 95% (68/72) patients achieved virologic response at week 4. Virologic response at end of treatment and sustained virologic response at 12\u00a0weeks after treatment were achieved by 94% (68/72) and 94% (68/72), respectively.ConclusionsIn Korean patients with genotype 1b CHC, 20.4% (29 of 142) of patients showed RAVs against NS5A inhibitors. Patient without RAVs who received treatment with DCV\u00a0+\u00a0ASV showed high virologic response rates in Korea.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12985-017-0826-1", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1034449", 
        "issn": [
          "1743-422X"
        ], 
        "name": "Virology Journal", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "keywords": [
      "resistance-associated variants", 
      "non-structural protein 5A inhibitors", 
      "interferon-based treatment", 
      "virologic response", 
      "Korean patients", 
      "liver cirrhosis", 
      "presence of RAVs", 
      "baseline NS5A resistance-associated variants", 
      "previous interferon-based treatment", 
      "NS5A resistance-associated variants", 
      "higher virologic response rates", 
      "chronic hepatitis C treatment", 
      "efficacy of DAAs", 
      "CHC genotype 1b", 
      "virologic response rates", 
      "hepatitis C treatment", 
      "end of treatment", 
      "single referral hospital", 
      "asunaprevir treatment", 
      "asunaprevir therapy", 
      "hepatitis C", 
      "consecutive patients", 
      "referral hospital", 
      "genotype 1b", 
      "ResultsA total", 
      "week 4", 
      "NS5A inhibitors", 
      "patients", 
      "average age", 
      "response rate", 
      "daclatasvir", 
      "cirrhosis", 
      "treatment", 
      "prevalence", 
      "C treatment", 
      "inhibitors", 
      "BackgroundDirect", 
      "response", 
      "Y93H", 
      "hospital", 
      "therapy", 
      "antivirals", 
      "weeks", 
      "efficacy", 
      "age", 
      "total", 
      "DAA", 
      "short period", 
      "variants", 
      "CHC", 
      "aim", 
      "years", 
      "L31", 
      "period", 
      "study", 
      "rate", 
      "test", 
      "presence", 
      "ASV", 
      "time", 
      "end", 
      "Korea", 
      "existence", 
      "efficiency"
    ], 
    "name": "Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C", 
    "pagination": "164", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1091326412"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12985-017-0826-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28836992"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12985-017-0826-1", 
      "https://app.dimensions.ai/details/publication/pub.1091326412"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:02", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_740.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12985-017-0826-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12985-017-0826-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12985-017-0826-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12985-017-0826-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12985-017-0826-1'


 

This table displays all metadata directly associated to this object as RDF triples.

277 TRIPLES      21 PREDICATES      122 URIs      109 LITERALS      35 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12985-017-0826-1 schema:about N02f5ad879f1c4f038f03b513966ce7fb
2 N08c83f8558ea48ac8f804e110b289c7a
3 N0b052cd1301a48f7831518fd27c59c8b
4 N1c4baa5be22749f0aa0d8dd91aa11f8b
5 N1d53eb700703464b929f0d55f5118182
6 N2be2830d005543d49c20ebf5799b54b5
7 N357b9f743b7a458ca176d139f6535123
8 N3625c3b19a524d1a9f509556f1325f57
9 N3af8fc5e165c4c83bf0f971996232ec5
10 N6eff114d471e47bfbe1adf1402788443
11 N72de38c78a184f7f8e843fba71e97b2d
12 N741f0c154374463aa98fcf0c3531ad6d
13 N839d7cba3fae4f60be74cee710d59eaa
14 N86e0a81680d2414796fbd4db1578083d
15 N89b633f00bb64511a6ebb30c8c86d726
16 N8d48cefcd4dc46a7a313f2d39f78c067
17 N94370f2c9f664fdcbdd0aa2c7f165fd4
18 N94f94289542344d58113995a0eb6a120
19 Na4df5be2b8f34106a44dfdb84ee49daf
20 Na6f629c654384e329fe3e6a20c79a938
21 Na82b0e15aa3c428199cc473f10a644dd
22 Nb3d6f2ce005a400298a866d01ebc8abd
23 Nb6bce2c155ed4bf7803d8fbfc7c6fc92
24 Nc901392e8e254176900523057e06920a
25 Ncba48b69c65b48f9866f78c9365f3fa7
26 Ne54eb337e5094183921a4e7ae341a2d3
27 Nf7d206685d2643a390b8f22193855a49
28 Nfd786fb7983c42d9a6783131b3a457ed
29 anzsrc-for:11
30 anzsrc-for:1103
31 schema:author N4bba8acb94e244fa974c13f3581f8fc8
32 schema:citation sg:pub.10.1007/s00535-017-1353-y
33 sg:pub.10.1007/s12325-015-0221-5
34 sg:pub.10.1007/s12325-016-0354-1
35 sg:pub.10.1186/1743-422x-10-355
36 sg:pub.10.1186/s12985-015-0318-0
37 schema:datePublished 2017-08-24
38 schema:datePublishedReg 2017-08-24
39 schema:description BackgroundDirect-acting antivirals (DAAs) for chronic hepatitis C (CHC) treatment are tolerable and highly effective in a shorter period of time than before. However, resistance-associated variants (RAVs) can affect the efficacy of DAAs. The aim of this study was to investigate the real-life prevalence of RAVs against non-structural protein 5A (NS5A) inhibitors in Korean patients with genotype 1b chronic hepatitis C.MethodsAll consecutive patients with CHC genotype 1b who underwent a RAV test at a single referral hospital were enrolled.ResultsA total of 142 patients (male 53, female 89) were tested for RAVs. The average age of the patients was 58 years. Liver cirrhosis was found in 34.5% (49/142) of patients, and 19.0% (29/142) of patients had previously undergone interferon-based treatment. Twenty-nine patients (20.4%) had RAVs (Y93 or L31). Y93H, L31, or Y93H with L31 were detected in 22 (15.5%), 8 (5.6%), and 1 (0.7%) patients, respectively. The presence of RAV was not affected by previous interferon-based treatment or by the existence of liver cirrhosis. Among 113 patients without baseline NS5A RAVs, 72 patients started daclatasvir (DCV) + asunaprevir (ASV) treatment and 95% (68/72) patients achieved virologic response at week 4. Virologic response at end of treatment and sustained virologic response at 12 weeks after treatment were achieved by 94% (68/72) and 94% (68/72), respectively.ConclusionsIn Korean patients with genotype 1b CHC, 20.4% (29 of 142) of patients showed RAVs against NS5A inhibitors. Patient without RAVs who received treatment with DCV + ASV showed high virologic response rates in Korea.
40 schema:genre article
41 schema:isAccessibleForFree true
42 schema:isPartOf N0516289615334cbc960622cb14663c28
43 N26bd4c3f06ff42d49a859b469389dbeb
44 sg:journal.1034449
45 schema:keywords ASV
46 BackgroundDirect
47 C treatment
48 CHC
49 CHC genotype 1b
50 DAA
51 Korea
52 Korean patients
53 L31
54 NS5A inhibitors
55 NS5A resistance-associated variants
56 ResultsA total
57 Y93H
58 age
59 aim
60 antivirals
61 asunaprevir therapy
62 asunaprevir treatment
63 average age
64 baseline NS5A resistance-associated variants
65 chronic hepatitis C treatment
66 cirrhosis
67 consecutive patients
68 daclatasvir
69 efficacy
70 efficacy of DAAs
71 efficiency
72 end
73 end of treatment
74 existence
75 genotype 1b
76 hepatitis C
77 hepatitis C treatment
78 higher virologic response rates
79 hospital
80 inhibitors
81 interferon-based treatment
82 liver cirrhosis
83 non-structural protein 5A inhibitors
84 patients
85 period
86 presence
87 presence of RAVs
88 prevalence
89 previous interferon-based treatment
90 rate
91 referral hospital
92 resistance-associated variants
93 response
94 response rate
95 short period
96 single referral hospital
97 study
98 test
99 therapy
100 time
101 total
102 treatment
103 variants
104 virologic response
105 virologic response rates
106 week 4
107 weeks
108 years
109 schema:name Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C
110 schema:pagination 164
111 schema:productId N44d057b3f12947029964f4ea7978049d
112 Ncf5abca7321c40c48cee4710aacbcb34
113 Nd69d5c1f7c404c6d9de6517f728d351d
114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091326412
115 https://doi.org/10.1186/s12985-017-0826-1
116 schema:sdDatePublished 2022-11-24T21:02
117 schema:sdLicense https://scigraph.springernature.com/explorer/license/
118 schema:sdPublisher N5a43a552e35f4226a6a4a188e5a345aa
119 schema:url https://doi.org/10.1186/s12985-017-0826-1
120 sgo:license sg:explorer/license/
121 sgo:sdDataset articles
122 rdf:type schema:ScholarlyArticle
123 N02f5ad879f1c4f038f03b513966ce7fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Interferons
125 rdf:type schema:DefinedTerm
126 N0516289615334cbc960622cb14663c28 schema:issueNumber 1
127 rdf:type schema:PublicationIssue
128 N08c83f8558ea48ac8f804e110b289c7a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Base Sequence
130 rdf:type schema:DefinedTerm
131 N0b052cd1301a48f7831518fd27c59c8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Carbamates
133 rdf:type schema:DefinedTerm
134 N1c4baa5be22749f0aa0d8dd91aa11f8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Hepatitis C, Chronic
136 rdf:type schema:DefinedTerm
137 N1d53eb700703464b929f0d55f5118182 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Prevalence
139 rdf:type schema:DefinedTerm
140 N26bd4c3f06ff42d49a859b469389dbeb schema:volumeNumber 14
141 rdf:type schema:PublicationVolume
142 N2be2830d005543d49c20ebf5799b54b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Male
144 rdf:type schema:DefinedTerm
145 N2de3ed863a134f6ca2f5483f08820b73 rdf:first sg:person.01136317651.80
146 rdf:rest N51d473275cf04aeba27d4ee8ba6eea5a
147 N357b9f743b7a458ca176d139f6535123 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Sulfonamides
149 rdf:type schema:DefinedTerm
150 N3625c3b19a524d1a9f509556f1325f57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Aged, 80 and over
152 rdf:type schema:DefinedTerm
153 N3af8fc5e165c4c83bf0f971996232ec5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Hepacivirus
155 rdf:type schema:DefinedTerm
156 N44d057b3f12947029964f4ea7978049d schema:name pubmed_id
157 schema:value 28836992
158 rdf:type schema:PropertyValue
159 N4bba8acb94e244fa974c13f3581f8fc8 rdf:first sg:person.01010326240.67
160 rdf:rest N2de3ed863a134f6ca2f5483f08820b73
161 N51d473275cf04aeba27d4ee8ba6eea5a rdf:first sg:person.01017047320.36
162 rdf:rest N739a0c16fd8e4fd8a581bb99d5907a7f
163 N5a43a552e35f4226a6a4a188e5a345aa schema:name Springer Nature - SN SciGraph project
164 rdf:type schema:Organization
165 N6eff114d471e47bfbe1adf1402788443 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name RNA, Viral
167 rdf:type schema:DefinedTerm
168 N72de38c78a184f7f8e843fba71e97b2d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Humans
170 rdf:type schema:DefinedTerm
171 N739a0c16fd8e4fd8a581bb99d5907a7f rdf:first sg:person.0634505520.15
172 rdf:rest rdf:nil
173 N741f0c154374463aa98fcf0c3531ad6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Pyrrolidines
175 rdf:type schema:DefinedTerm
176 N839d7cba3fae4f60be74cee710d59eaa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Imidazoles
178 rdf:type schema:DefinedTerm
179 N86e0a81680d2414796fbd4db1578083d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Liver Cirrhosis
181 rdf:type schema:DefinedTerm
182 N89b633f00bb64511a6ebb30c8c86d726 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Viral Nonstructural Proteins
184 rdf:type schema:DefinedTerm
185 N8d48cefcd4dc46a7a313f2d39f78c067 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Middle Aged
187 rdf:type schema:DefinedTerm
188 N94370f2c9f664fdcbdd0aa2c7f165fd4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Isoquinolines
190 rdf:type schema:DefinedTerm
191 N94f94289542344d58113995a0eb6a120 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Adult
193 rdf:type schema:DefinedTerm
194 Na4df5be2b8f34106a44dfdb84ee49daf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Treatment Failure
196 rdf:type schema:DefinedTerm
197 Na6f629c654384e329fe3e6a20c79a938 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Drug Combinations
199 rdf:type schema:DefinedTerm
200 Na82b0e15aa3c428199cc473f10a644dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Genotype
202 rdf:type schema:DefinedTerm
203 Nb3d6f2ce005a400298a866d01ebc8abd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Sustained Virologic Response
205 rdf:type schema:DefinedTerm
206 Nb6bce2c155ed4bf7803d8fbfc7c6fc92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Republic of Korea
208 rdf:type schema:DefinedTerm
209 Nc901392e8e254176900523057e06920a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Drug Resistance, Viral
211 rdf:type schema:DefinedTerm
212 Ncba48b69c65b48f9866f78c9365f3fa7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Female
214 rdf:type schema:DefinedTerm
215 Ncf5abca7321c40c48cee4710aacbcb34 schema:name dimensions_id
216 schema:value pub.1091326412
217 rdf:type schema:PropertyValue
218 Nd69d5c1f7c404c6d9de6517f728d351d schema:name doi
219 schema:value 10.1186/s12985-017-0826-1
220 rdf:type schema:PropertyValue
221 Ne54eb337e5094183921a4e7ae341a2d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
222 schema:name Aged
223 rdf:type schema:DefinedTerm
224 Nf7d206685d2643a390b8f22193855a49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
225 schema:name Antiviral Agents
226 rdf:type schema:DefinedTerm
227 Nfd786fb7983c42d9a6783131b3a457ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
228 schema:name Valine
229 rdf:type schema:DefinedTerm
230 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
231 schema:name Medical and Health Sciences
232 rdf:type schema:DefinedTerm
233 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
234 schema:name Clinical Sciences
235 rdf:type schema:DefinedTerm
236 sg:journal.1034449 schema:issn 1743-422X
237 schema:name Virology Journal
238 schema:publisher Springer Nature
239 rdf:type schema:Periodical
240 sg:person.01010326240.67 schema:affiliation grid-institutes:grid.15444.30
241 schema:familyName Yu
242 schema:givenName Jung Hwan
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010326240.67
244 rdf:type schema:Person
245 sg:person.01017047320.36 schema:affiliation grid-institutes:grid.15444.30
246 schema:familyName Lee
247 schema:givenName Kwan Sik
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017047320.36
249 rdf:type schema:Person
250 sg:person.01136317651.80 schema:affiliation grid-institutes:grid.15444.30
251 schema:familyName Lee
252 schema:givenName Jung Il
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136317651.80
254 rdf:type schema:Person
255 sg:person.0634505520.15 schema:affiliation grid-institutes:grid.15444.30
256 schema:familyName Kim
257 schema:givenName Ja Kyung
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634505520.15
259 rdf:type schema:Person
260 sg:pub.10.1007/s00535-017-1353-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1085710678
261 https://doi.org/10.1007/s00535-017-1353-y
262 rdf:type schema:CreativeWork
263 sg:pub.10.1007/s12325-015-0221-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011803667
264 https://doi.org/10.1007/s12325-015-0221-5
265 rdf:type schema:CreativeWork
266 sg:pub.10.1007/s12325-016-0354-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017346594
267 https://doi.org/10.1007/s12325-016-0354-1
268 rdf:type schema:CreativeWork
269 sg:pub.10.1186/1743-422x-10-355 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026883385
270 https://doi.org/10.1186/1743-422x-10-355
271 rdf:type schema:CreativeWork
272 sg:pub.10.1186/s12985-015-0318-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005521011
273 https://doi.org/10.1186/s12985-015-0318-0
274 rdf:type schema:CreativeWork
275 grid-institutes:grid.15444.30 schema:alternateName Gangnam Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, 20, 63-gil, Eonju-ro Gangnam-gu, 06229, Seoul, South Korea
276 schema:name Gangnam Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, 20, 63-gil, Eonju-ro Gangnam-gu, 06229, Seoul, South Korea
277 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...